Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. (HSCS) Stock Overview
Explore Heart Test Laboratories, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
6.2M
P/E Ratio
-0.00
EPS (TTM)
$-7.61
ROE
-1.75%
HSCS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Heart Test Laboratories, Inc. (HSCS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 77.33, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.34.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 6.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Andrew Simpson
15
550 Reserve Street, Southlake, TX
2022